KPV vs BPC-157: Inflammation, Gut and Skin, and Whether to Combine Them

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee. Current pricing always lives on each product page; the table is a guide to which product fits which goal.

What it is

KPV is a tripeptide, lysine-proline-valine, the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body makes from pro-opiomelanocortin. Alpha-MSH drives pigmentation, but it also acts as an anti-inflammatory signal. Researchers noticed the anti-inflammatory effect tracked with the tail of the molecule, and a 2008 review in Endocrine Reviews describes the three-amino-acid fragment keeping much of that activity while pigmentation depends on a different part of the sequence. KPV is not a steroid, not a hormone in its own right, and not a tanning peptide. The full reference is at what is KPV.

How KPV is described to work

• Entry through PepT1. A 2008 paper in Gastroenterology reported that KPV is carried into intestinal cells by PepT1, the transporter the gut lining uses to absorb small peptides, and that its effect depended on that transporter. PepT1 is described as upregulated in inflamed intestinal tissue.
• NF-kB and MAPK. Once inside, KPV is described as interfering with NF-kB and MAPK, two of the main pathways that turn an inflammatory trigger into a response. A 2012 paper in the International Journal of Physiology, Pathophysiology and Pharmacology reported this in human bronchial epithelial cells, through a route that did not depend on the pigment receptor.
• Lower cytokine output. In cell and mouse work the result is less TNF-alpha, IL-6, IL-1beta and IL-8. It is a "less fuel on the fire" description rather than "puts the fire out."

All of the mechanism work is in cells and animals.

What it is

BPC-157 is a pentadecapeptide, fifteen amino acids in the sequence GEPPPGKPADDAGLV, a partial sequence of a protein originally isolated from human gastric juice. The literature calls it "stable gastric pentadecapeptide BPC 157" because laboratory work reported it staying intact in gastric juice for hours. The gut is where its research began; the tendon and soft-tissue work came later. It is not a hormone or a steroid. The full reference is at what is BPC-157.

How BPC-157 is described to work

• New blood vessels. Animal work describes BPC-157 activating the VEGFR2 receptor and downstream nitric-oxide signalling, the axis the body uses to grow blood vessels into healing tissue.
• Cell migration. Cell studies describe activation of the FAK-paxillin pathway in tendon fibroblasts, which governs how cells attach and move into a wound.
• Gut-lining protection. The largest body of BPC-157 research describes protection of the stomach and intestinal lining against NSAIDs and alcohol in animal models. A 2020 paper in Current Pharmaceutical Design reported, in cell and rat models of NSAID damage, stabilized intestinal permeability and tight-junction integrity.

All of the mechanism work is in animals and cells.

The real difference is the job, not the strength

People often ask which is "stronger." No study has measured both in the same people, or measured either in people for inflammation at all. The useful difference is what each is described as doing: KPV turns down a signal, BPC-157 supports a repair process. That is why they are combined more often than chosen between.

Yes, they are frequently prescribed together, on the rationale that one addresses inflammatory signalling and the other tissue repair. No study has tested the combination, so it means two unknowns at once rather than one. Some people start with one, keep a simple log for four weeks, and add the second only if there is a reason to. Others want both in one injection. Pepti has three blends that contain both:

• KLOW suits gut or inflammation complaints alongside a skin or connective-tissue goal. See what is KLOW.
• ELEVATE suits a gut complaint entangled with mood or concentration complaints. See what is ELEVATE.
• FORTIFY suits gut symptoms alongside frequent infections or an immune reason for thymosin alpha-1. See what is FORTIFY.

There is no Pepti blend of KPV and BPC-157 alone. On their own, each is one variable, which makes it easier to judge what is doing what; a blend is a convenience, not a stronger version. Can you take two peptides together covers the general question.

KPV has no human studies. That is the FDA's finding in its review for the July 2026 advisory committee: no published studies in which KPV products were used in humans, and none of the nine references the nominator cited were human studies. The evidence is cell work, including human intestinal, T-cell and bronchial cell lines, and mouse models of colitis, skin inflammation and brain injury. The 2008 Inflammatory Bowel Diseases and Gastroenterology papers reported reduced colitis severity in mice, much of it with KPV given orally in drinking water; the subcutaneous route prescribers use has not been compared.

BPC-157 has very limited human data. The FDA's review identified one randomized, double-blind, placebo-controlled study: a two-week enema trial in 53 people with mild to moderate ulcerative colitis, reported only as a 2005 conference abstract. The confidence interval for the difference between groups crossed zero, and the reviewers judged the data inadequate to support efficacy. Beyond that, a phase 1 oral tablet study in healthy volunteers with no results posted and a 2025 pilot of intravenous infusion in two healthy people. There is no randomized human trial of the injectable form for any indication. The animal literature, by contrast, is extensive and internally consistent.

Neither has been shown in people to reduce inflammation, protect the gut lining or improve skin. Physicians prescribe both on mechanism plus clinical experience. The accurate framing is "described in preclinical research and used clinically," not "shown to work in people."

Both were placed in Category 2 of the FDA's 503A bulk substances list in 2023. As of the FDA pages checked in September 2026:

A committee vote is a recommendation, not a decision. Both remain legal to prescribe and dispense as compounded medications. Compounded medications are not FDA approved, and neither KPV nor BPC-157 is an FDA-approved drug. Are peptides FDA approved explains the difference.

Both are injected under the skin (subcutaneously) into the abdomen or thigh, rotating sites. The schedules differ:

• KPV: 0.25 mL, 25 units on a U-100 insulin syringe, once daily Monday through Friday. At 2 mg/mL that is 0.5 mg per dose, 20 doses per vial, about four weeks.
• BPC-157: 0.18 mL, 18 units, once daily. At 1 mg/mL that is 0.18 mg per dose, 27 doses per vial, about 3.9 weeks. It also comes as a pre-filled Pen cartridge.
• The blends that contain both are dosed at 0.25 mL once daily Monday through Friday, 20 doses per vial.

You do not need to calculate anything: your directions are printed on the vial, and your physician sets them after reviewing your intake. Refills run every 28 days, one vial at a time. Both ship refrigerated with ice packs and stay in the fridge between doses. Technique is covered in how to inject peptides safely.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

KPV. Described as well tolerated in the published animal work, which has not reported toxicity at the doses studied. Reported clinically: injection-site redness, mild soreness or bruising, and some early mild nausea or a transient headache. With no human trials, "well tolerated" means nothing concerning has emerged, not that it has been tested.

BPC-157. Described in animal work as having a wide margin between effective doses and doses that cause problems. Reported clinically: injection-site redness, mild soreness or bruising, and some early nausea or light-headedness. In the enema studies, headache and flatulence were the most frequent adverse events, with no serious ones.

Neither has an established interaction list. Anyone on immunosuppressants or biologic therapy should raise that specifically. Stop and contact your physician for any reaction that is severe, spreading, or involves difficulty breathing.

Neither can be bought legitimately without a prescription. Sites selling them "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a state-licensed, FDA-registered US pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti prescribes both in all 50 states and DC. Step-by-step pages: how to get KPV prescribed online, how to get BPC-157 prescribed online and how to get KLOW prescribed online.